Atrial Fibrillation Drugs Market: Overview
Atrial fibrillation is the most common sustained cardiac arrhythmia disorder across the globe. It is caused by degeneration of the electrical impulses in the upper cardiac chambers (atria) of the heart leading to chaotic rhythm. Advancing age, diabetes, high blood pressure, obesity, excessive alcohol consumption, chronic kidney disease, and ischemic heart disease are the major risk factors for atrial fibrillation.
Read Report Overview – https://www.transparencymarketresearch.com/atrial-fibrillation-drugs-market.html
According to the American Heart Association, the lifetime risk of developing atrial fibrillation is 25% for individuals aged 40 years and above. Atrial fibrillation leads to increased hospitalization rate, impaired quality of life, and increased risk of stroke and death. Atrial fibrillation medications are used to control the heart rate and rhythm by preventing blood clots which leads to effective management of the disease. Warfarin, Apixaban, Sotalol, Esmalol, Verapamil, and Dofetilide are some of the atrial fibrillation drugs currently available in the market.
Atrial Fibrillation Drugs Market: Key Trends
Increase in the number of elderly patients and rise in prevalence of atrial fibrillation across the globe are the major factors driving the global atrial fibrillation drugs market. According to the Centers for Disease Control and Prevention (CDC), 2.7 million to 6.1 million people in the U.S. are suffering from atrial fibrillation and the number is expected to reach 12.1 million by 2030. This is projected to fuel the demand for atrial fibrillation drugs during the forecast period.
Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=66692
Increase in the geriatric population is a major factor contributing to high prevalence of atrial fibrillation, which in turn is anticipated to propel the market in the next few years. For instance, prevalence of atrial fibrillation increases with age, affecting around 10% of the population aged 80 years and above. However, high cost of anticoagulants and complications associated with the use of atrial fibrillation drugs including shortness of breath, low blood pressure, seizures, slow heart rate, fainting, hallucinations, and heart palpitations are likely to restrain the global market from 2019 to 2027.
Atrial Fibrillation Drugs Market: Segmentation
The global atrial fibrillation drugs market can be segmented based on drug class, type, route of administration, end-user, and region. In terms of drug class, the market can be categorized into calcium channel blockers, beta-adrenergic receptor blockers, cardiac glycosides, antiarrhythmic drugs, anticoagulants, and antiplatelet agents. The anticoagulants segment held considerable share of the global market in 2018.
Based on type, the global atrial fibrillation drugs market can be divided into paroxysmal, persistent, and long-standing atrial fibrillation. In terms of route of administration, the global market can be bifurcated into oral and injectable. Based on end-user, the global atrial fibrillation drugs can be classified into hospitals, ambulatory surgical centers, and others.
Request for Custom Research – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=66692
Atrial Fibrillation Drugs Market: Regional Analysis
The global atrial fibrillation drugs market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for the largest share of the global market between 2019 and 2027. Rise in prevalence of cardiovascular diseases such as atrial fibrillation among the aging patient pool, presence of leading drug manufacturers in the U.S., and favorable reimbursement scenario for cardiac surgeries are anticipated to drive demand for atrial fibrillation drugs in the country.
According to CDC, 9% of the geriatric population aged 65 and above has atrial fibrillation in the country. High geriatric patient pool with cardiac disorders and rise in prevalence of atrial fibrillation is expected to drive demand for atrial fibrillation therapeutics in Europe in the next few years. For instance, atrial fibrillation affects approximately 4.5 million people in countries in Europe. Rapid adoption of western lifestyle, which increases the risk of cardiac diseases, and surge in the baby boomer population suffering from cardiovascular ailments in the developing countries such as India and China are the key factors boosting the atrial fibrillation drugs market in Asia Pacific.
Pre Book Atrial Fibrillation Drugs Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=66692<ype=S
Atrial Fibrillation Drugs Market: Competitive Landscape
Key players operating in the global atrial fibrillation drugs market are Pfizer, GlaxoSmithKline, Johnson & Johnson, Sanofi, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Acesion Pharma, and Bristol-Myers Squibb Co. These players focus on research and development activities for innovative product launches, as well as mergers & acquisitions to expand product portfolio and enhance geographic presence.
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453